| Elias I-hsin Hsu, MD | |
|
2777 Mile High Stadium Cir, Denver, CO 80211-5222 | |
| (303) 825-8822 | |
| Not Available |
| Full Name | Elias I-hsin Hsu |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 22 Years |
| Location | 2777 Mile High Stadium Cir, Denver, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902077332 | NPI | - | NPPES |
| 74153021 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | M9361 (Texas) | Secondary |
| 208800000X | Urology | BP30019030 (Texas) | Secondary |
| 208800000X | Urology | 47409 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lutheran Medical Center | Wheat ridge, CO | Hospital |
| Presbyterian St Luke's Medical Center | Denver, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Urology Center Of Colorado Pc | 2466349022 | 26 |
News Archive
The U.S. Food and Drug Administration today announced a final rule establishing regulations to require current good manufacturing practices (cGMP) for dietary supplements.
As disability law firms throughout the country prepare for 2010 Social Security Disability application cases, the disability lawyers at Berry & Associates have gotten a head start with an upgrade to their website, nationaldisabilitylawyer.com.
Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.
The majority of cancer doctors, patients, and members of the general public support cutting health care costs by refusing to pay for drugs that don't improve survival or quality of life, according to results of a new study that will be presented by researchers from the Perelman School of Medicine at the University of Pennsylvania during the annual meeting of the American Society of Clinical Oncology in Chicago in early June (Abstract #6518).
› Verified 6 days ago
| Entity Name | The Urology Center Of Colorado Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548280035 PECOS PAC ID: 2466349022 Enrollment ID: O20040301000224 |
News Archive
The U.S. Food and Drug Administration today announced a final rule establishing regulations to require current good manufacturing practices (cGMP) for dietary supplements.
As disability law firms throughout the country prepare for 2010 Social Security Disability application cases, the disability lawyers at Berry & Associates have gotten a head start with an upgrade to their website, nationaldisabilitylawyer.com.
Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.
The majority of cancer doctors, patients, and members of the general public support cutting health care costs by refusing to pay for drugs that don't improve survival or quality of life, according to results of a new study that will be presented by researchers from the Perelman School of Medicine at the University of Pennsylvania during the annual meeting of the American Society of Clinical Oncology in Chicago in early June (Abstract #6518).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elias I-hsin Hsu, MD 2777 Mile High Stadium Cir, Denver, CO 80211-5222 Ph: (303) 825-8822 | Elias I-hsin Hsu, MD 2777 Mile High Stadium Cir, Denver, CO 80211-5222 Ph: (303) 825-8822 |
News Archive
The U.S. Food and Drug Administration today announced a final rule establishing regulations to require current good manufacturing practices (cGMP) for dietary supplements.
As disability law firms throughout the country prepare for 2010 Social Security Disability application cases, the disability lawyers at Berry & Associates have gotten a head start with an upgrade to their website, nationaldisabilitylawyer.com.
Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.
The majority of cancer doctors, patients, and members of the general public support cutting health care costs by refusing to pay for drugs that don't improve survival or quality of life, according to results of a new study that will be presented by researchers from the Perelman School of Medicine at the University of Pennsylvania during the annual meeting of the American Society of Clinical Oncology in Chicago in early June (Abstract #6518).
› Verified 6 days ago
Dr. John William Tillett, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2777 Mile High Stadium Cir, Denver, CO 80211 Phone: 303-825-8822 Fax: 303-825-4022 | |
Dr. Marklyn Jon Jones, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2777 Mile High Stadium Cir, Denver, CO 80211 Phone: 303-825-8822 Fax: 303-825-4022 | |
Dr. Michael Thomas Davenport, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Dr. Dustin R Ridout, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2045 Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Dr. Edward Allen Rhodes, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2005 E 18th Ave, Denver, CO 80206 Phone: 303-321-4212 Fax: 303-388-2459 | |
Milford Ray Painter Jr., Urology Medicare: Not Enrolled in Medicare Practice Location: 2635 Walnut St, Denver, CO 80205 Phone: 877-320-1692 | |
Austin Banning Derosa, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2777 Mile High Stadium Cir, Denver, CO 80211 Phone: 303-825-8822 Fax: 303-825-4022 |